Series A Round
Funding Details
HAYA Therapeutics is a precision medicines company focused on developing RNA-guided programmable therapeutics that target the regulatory genome to address chronic and age-related diseases. The company leverages the human genome's dark matter to create precise and potent RNA therapies aimed at reprogramming disease-driving cell states. This funding will expedite the clinical development of their lead candidate, HTX-001, aimed at treating heart failure and other chronic conditions. The investment will also support the expansion of their research capabilities and the advancement of their pipeline of innovative RNA therapies.
Confidence Score
Participating Investors
Sofinnova Partners is a leading European venture capital firm focused on life sciences and technology investments. They specialize in early-stage fund...
Earlybird Venture Capital is a leading European venture capital firm that invests in technology-driven companies at various stages of development, wit...
Eli Lilly and Company is a global pharmaceutical company that focuses on developing innovative medicines to improve patient outcomes. Through its corp...
Related Tweets
No tweets found for this funding round.